<DOC>
	<DOCNO>NCT01448902</DOCNO>
	<brief_summary>The study ass efficacy OC000459 200 mg twice daily orally comparison placebo subject challenge Vienna Challenge Chamber 6 hour . This randomise , double blind , placebo control , two way crossover evaluation . There screen period three week washout period least one week two treatment period . There follow one three week last dose study drug .</brief_summary>
	<brief_title>A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Indoleacetic Acids</mesh_term>
	<criteria>Males age 18 50 year history symptom grass pollen relate allergic rhinitis within previous two year . Subjects must free significant cardiac , pulmonary , gastrointestinal , hepatic , renal , haematological , neurological psychiatric disease determine history , physical examination screen investigation . FEV1 within normal limit ( â‰¥90 % predict ) . Atopy define positive cutaneous response mixed grass pollen within last 12 month screen . Asymptomatic screening Non smoker least past 12 month Medical condition likely affect outcome study . Nasal condition likely affect outcome study , i.e . nasal septal perforation , nasal polyp , sinus disease , chronic nasal obstruction , nasal disease . Presence respiratory disease history mild stable asthma require treatment associate normal lung function Immunotherapy treatment course include inhaled local corticosteroid past 28 day .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>CRTH2</keyword>
</DOC>